Eli Lilly raises forecasts on surging demand for weight-loss drugs

(Reuters) -Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it blow past third-quarter earnings estimates. Shares of the company, the world's largest healthcare firm by market capitalization, jumped 7% in premarket trading. Investors were keenly awaiting latest results from the drugmaker amid sky-high expectations for its GLP-1 portfolio and growing concern over potential U.S. pric ...